Skip to main content
HYUNDAI BIOSCIENCE CO., LTD. logo

HYUNDAI BIOSCIENCE CO., LTD. — Investor Relations & Filings

Ticker · 048410 ISIN · KR7048410005 KO Professional, scientific and technical activities
Open in API
Filings indexed 288 across all filing types
Latest filing 2026-02-25 Management Reports
Country KR South Korea
Listing KO 048410

About HYUNDAI BIOSCIENCE CO., LTD.

http://www.hyundaibioscience.com/eindex…

HYUNDAI BIOSCIENCE CO., LTD. is a biotechnology company focused on developing innovative therapeutics using its proprietary drug delivery system (DDS) technology. The company's core science is based on organic-inorganic hybrid technologies designed to safely and effectively deliver active ingredients. Its main development pipeline includes CP-COV03, a broad-spectrum antiviral agent that enhances cellular autophagy to combat viral infections, and Polytaxel, an anticancer drug candidate developed with polymer transfer technologies to reduce toxicity. The company's primary focus is on creating novel treatments for viral diseases and cancer.

Recent filings

Filing Released Lang Actions
매출액또는손익구조30%(대규모법인은15%)이상변동
Management Reports Classification · 95% confidence The document is a formal regulatory filing from a Korean company (Hyundai Bioscience) titled 'Change in Sales or Profit/Loss Structure of 30% or more'. This type of disclosure is a standard mandatory regulatory filing in the Korean market (DART system) used to announce significant changes in financial performance before the final audited annual report is released. It provides key financial highlights, reasons for the variance, and comparative data. Since it is an initial announcement of financial results (key highlights) rather than the full annual report or a simple publication notice, it falls under the 'Earnings Release' category.
2026-02-25 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 95% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and includes a '정정신고' (Correction Report) header. It details the issuance of stock options to employees and executives, including specific terms, exercise prices, and valuation methods. This type of disclosure regarding capital structure changes and equity-based compensation falls under the category of share issues or capital changes.
2026-02-20 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 95% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and specifically marked as a '정정 신고' (Correction Report). It details adjustments to previously reported stock option grants due to a bonus issue (무상증자) and employee resignations. This type of filing, which reports changes to capital-related instruments like stock options, falls under the category of share and capital changes.
2026-02-13 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 98% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on the Granting of Stock Options) submitted to the Financial Services Commission/Korea Exchange. It details the issuance of stock options to employees and executives, including the number of shares, exercise price, and vesting conditions. This type of disclosure regarding capital structure changes and employee compensation via stock options falls under the category of 'Share Issue/Capital Change' (SHA) in the provided schema.
2026-02-13 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act (Article 147). It details changes in share ownership, including major shareholding notifications, changes in special relationships, and collateral agreements. This falls under the 'Major Shareholding Notification' category.
2026-01-23 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act (Article 147). This document details changes in share ownership, including major shareholding notifications, changes in special relationships, and details of stock collateral contracts. It is not an annual report, earnings release, or a simple announcement, but a formal disclosure of significant shareholding status, which falls under the 'Major Shareholding Notification' category.
2025-12-19 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.